NKF 2019—Patiromer allows patients with CKD to remain on spironolactone


  • Richard Robinson
  • Conference Reports
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Patients with treatment-resistant hypertension and advanced chronic kidney disease (CKD) can maintain spironolactone with a lower risk of potassium elevation.

Why this matters

  • Treatment-resistant hypertension is common in CKD, but CKD is a risk factor for hyperkalemia under spironolactone treatment.
  • Patiromer is indicated for treatment of hyperkalemia.

Study design

  • Randomized, international, multicenter trial of 12 weeks of spironolactone + placebo vs spironolactone + patiromer (n=295).
  • Patients had:
    • uncontrolled hypertension while taking at least 3 antihypertensive medications,
    • estimated glomerular filtration rate of 25-45 mL/minute/1.73 m2 (advanced CKD).
  • Primary endpoint: Between-group difference in the proportion of subjects remaining on spironolactone at week 12.
  • Funding: Relypsa.

Key results

  • At 12 weeks, 86% of patients on patiromer vs 66% of patients on placebo remained on spironolactone (least-squares [LS] difference between groups, 20%; 95% CI, 10%-29%; P<.0001>
  • Patiromer favored for:
    • time to discontinuation of spironolactone (P=.0001),
    • time to serum K+ ≥5.5 mEq/L (P≤.0001),
    • cumulative dose of spironolactone (LS mean difference between groups: 385 mg; 95% CI, 140-629; P=.0021).
  • No difference in BP control between groups.
  • No treatment-attributed serious adverse events.

 

Please confirm your acceptance

To gain full access to GPnotebook please confirm:

By submitting here you confirm that you have accepted Terms of Use and Privacy Policy of GPnotebook.

Submit